Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.65
SPPI's Cash to Debt is ranked lower than
72% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. SPPI: 1.65 )
Ranked among companies with meaningful Cash to Debt only.
SPPI' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 8.76 Max: 17918
Current: 1.65
0.2
17918
Equity to Asset 0.56
SPPI's Equity to Asset is ranked lower than
63% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SPPI: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
SPPI' s Equity to Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.58 Max: 0.95
Current: 0.56
0.2
0.95
F-Score: 3
Z-Score: 0.18
M-Score: -2.80
WACC vs ROIC
9.07%
-26.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -29.30
SPPI's Operating margin (%) is ranked higher than
61% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. SPPI: -29.30 )
Ranked among companies with meaningful Operating margin (%) only.
SPPI' s Operating margin (%) Range Over the Past 10 Years
Min: -484.81  Med: -45.89 Max: 30.17
Current: -29.3
-484.81
30.17
Net-margin (%) -34.19
SPPI's Net-margin (%) is ranked higher than
59% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. SPPI: -34.19 )
Ranked among companies with meaningful Net-margin (%) only.
SPPI' s Net-margin (%) Range Over the Past 10 Years
Min: -443.64  Med: -44.65 Max: 35.19
Current: -34.19
-443.64
35.19
ROE (%) -24.60
SPPI's ROE (%) is ranked higher than
57% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. SPPI: -24.60 )
Ranked among companies with meaningful ROE (%) only.
SPPI' s ROE (%) Range Over the Past 10 Years
Min: -72  Med: -23.84 Max: 39.19
Current: -24.6
-72
39.19
ROA (%) -12.86
SPPI's ROA (%) is ranked higher than
65% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. SPPI: -12.86 )
Ranked among companies with meaningful ROA (%) only.
SPPI' s ROA (%) Range Over the Past 10 Years
Min: -61.52  Med: -12.49 Max: 23.98
Current: -12.86
-61.52
23.98
ROC (Joel Greenblatt) (%) -5933.17
SPPI's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. SPPI: -5933.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPPI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5933.17  Med: -1954.97 Max: 3089.46
Current: -5933.17
-5933.17
3089.46
Revenue Growth (3Y)(%) -15.40
SPPI's Revenue Growth (3Y)(%) is ranked lower than
70% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SPPI: -15.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPPI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -4.6 Max: 202.1
Current: -15.4
0
202.1
» SPPI's 10-Y Financials

Financials (Next Earnings Date: 2017-03-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

SPPI Guru Trades in Q4 2015

Jim Simons 2,591,319 sh (+46.11%)
Paul Tudor Jones 39,787 sh (+30.63%)
» More
Q1 2016

SPPI Guru Trades in Q1 2016

Jim Simons 3,304,100 sh (+27.51%)
Paul Tudor Jones 11,976 sh (-69.90%)
» More
Q2 2016

SPPI Guru Trades in Q2 2016

Joel Greenblatt 39,070 sh (New)
Paul Tudor Jones 42,767 sh (+257.11%)
Jim Simons 4,558,117 sh (+37.95%)
» More
Q3 2016

SPPI Guru Trades in Q3 2016

Barrow, Hanley, Mewhinney & Strauss 238,988 sh (New)
Paul Tudor Jones 79,444 sh (+85.76%)
Jim Simons 5,541,957 sh (+21.58%)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AKBA, NAS:SRNE, NAS:CRBP, NAS:CEMP, NAS:MESO, NAS:SVA, NAS:ADAP, NAS:GERN, NAS:FOMX, NAS:NVAX, NAS:OMED, NAS:LJPC, NAS:BSTC, NAS:EDGE, NAS:SYRS, NAS:IMMU, OTCPK:TYMI, NAS:CRVS, NAS:VYGR, AMEX:BTX » details
Traded in other countries:NTR.Germany,
Spectrum Pharmaceuticals Inc is a biotechnology company with fully integrated commercial and drug development operations with a primary focus on oncology and hematology.

Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., and to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.

Ratios

vs
industry
vs
history
P/B 1.23
SPPI's P/B is ranked higher than
86% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. SPPI: 1.23 )
Ranked among companies with meaningful P/B only.
SPPI' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.05 Max: 5.24
Current: 1.23
0.64
5.24
P/S 1.67
SPPI's P/S is ranked higher than
88% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. SPPI: 1.67 )
Ranked among companies with meaningful P/S only.
SPPI' s P/S Range Over the Past 10 Years
Min: 1.06  Med: 3.27 Max: 449.23
Current: 1.67
1.06
449.23
Current Ratio 3.71
SPPI's Current Ratio is ranked lower than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. SPPI: 3.71 )
Ranked among companies with meaningful Current Ratio only.
SPPI' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.8 Max: 16.82
Current: 3.71
0.56
16.82
Quick Ratio 3.60
SPPI's Quick Ratio is ranked lower than
53% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. SPPI: 3.60 )
Ranked among companies with meaningful Quick Ratio only.
SPPI' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.66 Max: 16.8
Current: 3.6
0.56
16.8
Days Inventory 67.03
SPPI's Days Inventory is ranked higher than
73% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. SPPI: 67.03 )
Ranked among companies with meaningful Days Inventory only.
SPPI' s Days Inventory Range Over the Past 10 Years
Min: 67.03  Med: 109.12 Max: 281.63
Current: 67.03
67.03
281.63
Days Sales Outstanding 95.95
SPPI's Days Sales Outstanding is ranked lower than
71% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. SPPI: 95.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPPI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.09  Med: 100.74 Max: 138.24
Current: 95.95
9.09
138.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
SPPI's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. SPPI: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SPPI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -149.9  Med: -24.7 Max: -3.6
Current: -4.4
-149.9
-3.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.78
SPPI's Price/Net Current Asset Value is ranked lower than
68% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. SPPI: 9.78 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SPPI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.84  Med: 8.49 Max: 279.33
Current: 9.78
0.84
279.33
Price/Tangible Book 5.28
SPPI's Price/Tangible Book is ranked lower than
57% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. SPPI: 5.28 )
Ranked among companies with meaningful Price/Tangible Book only.
SPPI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.66  Med: 6.28 Max: 581.43
Current: 5.28
0.66
581.43
Price/Projected FCF 0.95
SPPI's Price/Projected FCF is ranked higher than
84% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. SPPI: 0.95 )
Ranked among companies with meaningful Price/Projected FCF only.
SPPI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.65 Max: 12.11
Current: 0.95
0.94
12.11
Price/Median PS Value 0.52
SPPI's Price/Median PS Value is ranked higher than
78% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. SPPI: 0.52 )
Ranked among companies with meaningful Price/Median PS Value only.
SPPI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 1.88 Max: 15937.5
Current: 0.52
0.18
15937.5
Earnings Yield (Greenblatt) (%) -19.14
SPPI's Earnings Yield (Greenblatt) (%) is ranked lower than
69% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. SPPI: -19.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPPI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -19.39  Med: 11.6 Max: 1754.4
Current: -19.14
-19.39
1754.4

More Statistics

Revenue (TTM) (Mil) $161.5
EPS (TTM) $ -0.78
Beta1.26
Short Percentage of Float14.99%
52-Week Range $3.21 - 7.74
Shares Outstanding (Mil)80.56

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 132 95 99 160
EPS ($) -1.10 -0.64 -0.02 0.55
EPS w/o NRI ($) -1.10 -0.64 -0.02 0.55
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
AT&T Will Benefit From DirecTV Acquistion Aug 14 2015 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
7:03 am Spectrum Pharma at ASH: Case match control analysis of Propel reveals survival advantage for... Dec 06 2016
Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the... Dec 06 2016
10 Major Pharma and FDA Catalysts Coming in December Dec 05 2016
Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at... Dec 05 2016
Spectrum Pharmaceuticals Highlights Four Abstracts at the 58th Annual Meeting of the American... Dec 02 2016
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Spectrum Pharmaceuticals, Inc. for... Nov 29 2016
Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SPPI-US :... Nov 29 2016
ETFs with exposure to Spectrum Pharmaceuticals, Inc. : November 28, 2016 Nov 28 2016
SPECTRUM PHARMACEUTICALS INC Financials Nov 23 2016
Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola Nov 23 2016
Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22,... Nov 22 2016
Spectrum Bladder Cancer Drug Nixed by FDA (SPPI) Nov 21 2016
Spectrum (SPPI) Gets CRL for Bladder Cancer Drug in U.S. Nov 21 2016
3-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Spectrum... Nov 18 2016
SPPI UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action... Nov 18 2016
Spectrum Pharma says U.S. FDA rejects its bladder cancer drug Nov 18 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 18 2016
UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Spectrum... Nov 17 2016
Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming November 21st... Nov 17 2016
Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference... Nov 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)